Last week a sleep‑deprived author tried the Zeus, a dark‑grey stick‑on device created by researchers at Guy’s and St. Thomas’ NHS Foundation Trust and King’s College London, to curb his newly‑emerged snoring. The gadget, which delivers transcutaneous electrical nerve stimulation (TENS) to the hypoglossal nerve, reportedly kept him asleep for several uninterrupted hours, a stark contrast to his previous fragmented nights.

Zeus targets the hypoglossal nerve with TENS to keep the airway open

The Zeus works by sending low‑level electrical pulses through the skin to the hypoglossal nerve, which controls tongue positioning. By preventing the tongue from collapsing backward, the device aims to stop the airway blockage that triggers snoring. According to the product’s developers, this method mirrors the principle behind more invasive hypoglossal nerve stimulation implants, but in a non‑surgical, adhesive format.

First‑hand trial delivered several hours of uninterrupted sleep

In the author’s initial night with Zeus, he experienced “uninterrupted sleep for several hours,” a noable improvement over his usual pattern of frequent awakenings caused by his own snoring. The report notes that the device’s effect was immediate, with the author hearing fewer snore bursts and waking less often. As the source states , the relief was “remarkable” compared with his prior sleep disturbances.

Development backed by Guy’s and St . Thomas’ NHS Trust and King’s College London

The Zeus was engineered by a joint team from Guy’s and St. Thomas’ NHS Foundation Trust and King’s College London, institutions known for clinical research in sleep medicine. Their collaboration suggests the device has undergone at least preliminary clinical evaluation,though the source does not detail the size or outcomes of any formal trials.

Who still needs to prove Zeus can replace CPAP?

While the author’s anecdote is encouraging, it leaves unanswered how Zeus stacks up against the gold‑standard continuous positive airway pressure (CPAP) therapy for obstructive sleep apnea. The source does not provide comparative data, nor does it clarify whether the device is approved for moderate or severe cases.. Additionally, long‑term adherence and any potential side effects of nightly TENS remain unaddressed.

Potential market impact if larger studies confirm early results

If broader clinical trials validate the author’s experience, Zeus could become a low‑cost, non‑invasive alternative for mild snorers and their partners. The device’s simplicity—just a stick‑on patch—might appeal to users who balk at bulky CPAP machines. However, as the source notes, the current evidence is limited to a single personal test, so widespread adoption will hinge on rigorous peer‑reviewed research.